AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-305-671-0200**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Omvoh™ SQ & IV (mirikizumab-mrkz)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight: _____ **Date:** _____

NOTE: The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

ATTENTION: Omvoh IV induction (loading dose) for treatment of ulcerative colitis can only be billed under the **MEDICAL BENEFIT**. NDC: 00002-7575-01; J3590

Adult Dosing:

- **Induction IV: NDC: 00002-7575-01 – Omvoh IV 300 mg/15 mL vial – J3590**
  - 300 mg administered by intravenous infusion over at least 30 minutes at Week 0, Week 4, and Week 8
- **Maintenance SubQ: NDC: 00002-8011-01/27 – Omvoh 100 mg/mL prefilled pen**
  - 200 mg administered by subcutaneous injection (given as two consecutive injections of 100 mg each) at Week 12, and every 4 weeks thereafter

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ **Maintenance Dose – 200 mg administered by subcutaneous injection (given as two consecutive injections of 100 mg each) at Week 12, and every 4 weeks thereafter**

Authorization Criteria: To be reviewed for approval under the pharmacy benefit

- ❑ Member has a diagnosis of **ulcerative colitis**
- ❑ Medication has been prescribed by a **Gastroenterologist**
- ❑ Member has moderate to severe active disease with inadequate response after a **90-day** trial of **ONE** of the following conventional therapies **(verified by chart notes or pharmacy paid claims)**:
  - ❑ 6-mercaptopurine
  - ❑ aminosalicylates (e.g., mesalamine, balsalazide, olsalazine)
  - ❑ sulfasalazine
  - ❑ azathioprine
  - ❑ corticosteroids (e.g., budesonide, high dose steroids: 40-60 mg of prednisone daily)
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **BOTH** of the following **PREFERRED** biologics:
    - ❑ **ONE** of the following adalimumab products:
      - ❑ Humira®
      - ❑ Cyltezo®
      - ❑ Hyrimoz®
    - ❑ Stelara® SQ
  - ❑ Member has been established on Omvoh™ prefilled pen for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Omvoh was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ **Induction Dose (If required) – One time approval for duration of 2 months, member to receive up to three (3) IV infusion doses**

Authorization Criteria: To be reviewed for one-time approval under the medical benefit

- ❑ Medication will be used as induction therapy

(Continued on next page)

- ❑ Medication being provided by:
  - ❑ **Location/site of drug administration:**_____
  - ❑ **NPI or DEA # of administering location**:_____
- ❑ Member to receive FDA approved loading dose of 300 mg administered by intravenous infusion over at least 30 minutes at Week 0, Week 4, and Week 8

Medication being provided by a Specialty Pharmacy – Proprium Rx

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee: 1/18/2024**
REVISED/UPDATED: 2/9/2024